NRG announces £16m Series A for IND for Parkinson’s and ALS
pharmaphorum
NOVEMBER 9, 2022
for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.
52 
Let's personalize your content